|
AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster
FierceBiotech Benralizumab–an IL-5 antibody–reduced the rate of asthma exacerbations, hitting the primary endpoint in the trial, says AstraZeneca ($AZN). But the study flagged weak results for the low end of the doses used in the trial, with the top dose doing … AstraZeneca share price: Novel drug shows positive results for severe asthma AstraZeneca's benralizumab succeeds in severe asthma |
View full post on asthma – Google News